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Objective: The purpose of this study was to determine the clinical outcome of patients undergoing catheter-directed
thrombolysis (CDT) for lower extremity arterial bypass (LEAB) occlusion.
Methods: A retrospective review was performed of two university-based practices from 1988 to 2001. All patients with
LEAB occlusion (<14 days by history) undergoing CDT as initial treatment were included. Technical success,
complications, secondary patency, and limb salvage were examined. Additional analysis examined secondary procedures
performed for residual lesions or failed CDT and the number of LEABs that were replaced or that became infected.
Results: One hundred four patients (77% male; mean age, 65 years) had 109 LEAB occlusions. CDT restored patency in
77%. Of the 25 LEABs that failed initial CDT, 15 underwent surgical thrombectomy/revision, four were replaced, and
six underwent no further interventions. Of the 84 LEABs successfully lysed, 51 had residual lesions that underwent
revision with interventional (n  30) or surgical (n  15) techniques or both (n  6). Median hospital stay was 8 days
with three periprocedural deaths. One quarter of CDT procedures had bleeding or thrombotic complications or both.
The mean follow-up period was 45 months. Secondary patency rates on an intention-to-treat basis (attempted
thrombolysis) were 32% and 19% at 1 and 5 years, respectively. After successful CDT, the 1-year secondary patency rate
was comparable in LEABs with or without residual lesions (42% versus 45%). Overall, the limb salvage rates were 73% and
55% at 1 and 5 years, respectively. The survival rate was 56% at 5 years. Ten of the 54 LEABs (19%) that eventually failed
after successful CDT had three or more reocclusive episodes. Seven LEABs (8.3%) salvaged with CDT eventually became
infected from recurrent interventions; six of these necessitated major amputation. Twenty LEABs initially salvaged with
CDT were replaced (four immediately and 16 after episodes of recurrent ischemia). Two patients died during
hospitalization for treatment of recurrent ischemia.
Conclusion: Despite relatively high initial technical success for LEAB thrombolysis, eventual failure is the rule rather than
the exception. Recurrent LEAB occlusions lead to significant morbidity, including recurrent interventions, eventual graft
infection/replacement, and limb loss. However, LEAB replacement has substantial problems associated with limited
conduit, reoperative anatomy, and subsequent wound complications. We therefore advocate an initial attempt at CDT
with liberal use of graft replacement for early and late failures or as an initial strategy in those with favorable remaining
conduit. (J Vasc Surg 2003;37:72-8.)
The management of acute lower extremity arterial by-
pass (LEAB) occlusion has been the subject of much debate
among vascular specialists. Catheter-directed thrombolysis
(CDT) offers the potential to open the LEAB and expose a
possible underlying lesion and offers treatment with either
angioplasty or surgical revision. This strategy has been the
subject of many reported clinical series1-6 and encompasses
a subgroup of patients involved in several randomized
trials.7-11 In addition, CDT has been one of the recom-
mended initial treatments for LEAB occlusion in the re-
cently reported TransAtlantic Guidelines.12 Proponents of
CDT for LEAB occlusion argue that limited intervention in
patients with many comorbidities, limited conduit, and
potentially abbreviated survival is prudent. If reocclusion
occurs, repeat CDT can be performed, reestablishing pa-
tency with minimal morbidity.
Proponents of graft replacement argue that the limited
early secondary patency rates of CDT for LEAB occlusion
are unacceptable. They propose that poor secondary pa-
tency is the result of intrinsically damaged LEABs and that
despite correction of underlying lesions, reocclusion re-
mains the rule. These reocclusive events may produce ma-
jor morbidity and increase limb loss.
Confounding data support both approaches. Patency
can be reestablished in most LEAB occlusions with
CDT.1-11 Secondary LEAB patency rates are inferior in
patients treated with CDT1-4,6 compared with primary
patency rates reported in series of replacement LEAB graft-
ing.13-15 However, repeat LEAB is associated with patient
morbidity related to wound healing, limb edema, and need
for additional surgery from wound or graft surveillance
problems.16 Our review assesses the long-term outcome of
CDT for treatment of acute LEAB occlusion.
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MATERIALS AND METHODS
This study was undertaken because two of the authors,
Drs Nehler and McLafferty, trained at an institution per-
forming graft replacement for LEAB occlusion and became
vascular faculty at institutions performing CDT for LEAB
occlusion. Because of these practice patterns, this review
does not have a comparable graft replacement arm but will
use series from the surgical literature as controls. With
vascular surgery databases at the Denver Veterans Affairs
Medical Center and Southern Illinois University in Spring-
field, Ill, all patients undergoing CDT for acute (14 days)
LEAB occlusion from January 1, 1988, to December 31,
2001, were identified. Patient records were reviewed for
demographic variables including age, gender, and the fol-
lowing risk factors: diabetes, hypertension, coronary artery
disease, prior coronary artery bypass surgery, congestive
heart failure, and dialysis-dependent renal disease. The
number of prior lower extremity vascular interventions and
the primary indication for the patient’s initial lower extrem-
ity revascularization were recorded. The duration of LEAB
patency before CDT was recorded.
Technique of CDT was intraarterial within the throm-
bus and consistent with other reports.9,11 After pulse spray,
urokinase was dosed at 150,000 to 200,000 units per hour.
Tissue plasminogen activator was dosed 0.3 mg/kg in 75
mL normal saline solution. This volume was pulsed in
2-mL to 3-mL increments, followed by a 0.05-mg/kg drip.
Concomittent heparin drip was frequently used with uroki-
nase but not with tissue plasminogen activator. Data re-
garding CDT for LEAB occlusions included: LEAB con-
duit (vein or prosthetic), LEAB anatomic configuration
(aortofemoral, extraantomic, femoropopliteal above-knee,
femoropopliteal below-knee, or femorotibial), duration of
CDT; the number of subsequent follow-up angiographic
studies per CDT, duration of CDT, success of CDT at
achieving LEAB patency, the presence of any residual
LEAB lesions identified after CDT, whether any endovas-
cular procedures were performed for residual lesions, and
information regarding any bleeding or thromboembolic
complications of CDT.
Information recorded after CDT included: hospital
stay, subsequent surgical revascularization procedures per-
formed, 30-day mortality, and major nonfatal morbidity.
Long-term data included: secondary graft patency, limb
salvage, survival, recurrent graft occlusions, management of
recurrent graft occlusions, additional hospitalizations for
complications related to CDT, incidence of graft infection,
and incidence of graft replacement.
Statistical analysis. Data were collected from record
review and entered into a relational database (Microsoft
Access, Redmond, Wash). Continuous variables were sum-
marized as mean  standard deviation or median and
range. Categoric variables were summarized as frequency
within each category and percent of population. Kaplan-
Meier product-limit estimates were used to summarize the
time to secondary graft patency, patient survival, and limb
salvage. Log-rank tests and univariate logistic regression
models were used to examine the relationship between
immediate CDT success or secondary LEAB patency in
infrainguinal grafts and days of symptoms, gender, graft
anatomy, and conduit.
RESULTS
One hundred four patients (mean age, 65  13 years;
range, 41 to 90 years) underwent CDT for 109 acute
LEAB occlusions. Table I shows patient demographics, risk
factors, and pertinent surgical history. The anatomic con-
figuration and conduit distribution of 109 occluded LEABs
undergoing CDT are presented in Table II. In 98 LEABs,
the original date of the surgery could be determined.
Median patency of these LEABs before CDT was 10
months, with 67% occluding before 2 years and 37% oc-
cluding before 6 months.
One hundred seven of 109 CDT procedures (98%)
were completed/abandoned within 48 hours. Median
number of angiographic studies during CDT was 2.8
(range, 1 to 5). Urokinase was used in 103 CDT proce-
dures (94%) and tissue plasminogen activator was used in
Table I. Demographics and risk factors for 107 patients
undergoing CDT for LEAB occlusion
Demographic or risk factor %
Male gender 77
Diabetes 32
Coronary artery disease 54
Prior CABG 27
Congestive heart failure 10
Hypertension 46
Dialysis dependence 5
Smokers total (current) 89 (48)
Contralateral BKA/AKA 12
Two or more prior revascularizations 60
Three or more prior revascularizations 34
Known first revascularization for claudication 40
Limb threat on LEAB occlusion presentation 88
CABG, Coronary artery bypass grafting; BKA, below-knee amputation;
AKA, above-knee amputation.
Table II. Characteristics of 112 LEAB occlusions
undergoing CDT
No. (%)
Suprainguinal 14 (13)
Aortic 6 (6)
Extraanatomic 8 (7)
Infrainguinal 95 (87)
Above-knee popliteal 22 (20)
Prosthetic 19
Autogenous 3
Below-knee popliteal 30 (27)
Prosthetic 6
Autogenous 24
Tibial 43 (39)
Prosthetic 8
Autogenous 35
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the remainder of CDT procedures. CDT was successful in
restoring patency in 84 LEABs (77%). Thirty-three LEABs
had no demonstrable lesions after successful CDT, but two
needed tibial embolectomy for distal embolization and two
others were replaced during the same hospitalization. Fifty-
one LEABs had residual lesions after CDT. Table III lists
the anatomic location of these lesions. The following inter-
ventions were performed for these lesions: percutaneous
transluminal angioplasty (n  30), percutaneous translu-
minal angioplasty followed by surgical revision to treat
additional or refractory outflow lesions (n  6), and surgi-
cal revision or graft replacement of long segment graft or
tibial lesions, including embolectomy of distal emboli (n
15). Twenty-five LEABs (23%) failed CDT. Fifteen under-
went surgical thrombectomy and revision, four were re-
placed, and six underwent no further revision. Of these, 18
limbs were initially salvaged and seven underwent near-
term (within 30 days) major amputation.
The median hospital stay was 8 days (range, 2 to 73
days). Complications are described in Table IV. There were
three periprocedural deaths (2.7%; two fatal myocardial
infarctions and one ruptured thoracic aortic aneurysm).
Fourteen patients (14%) had bleeding complications, of
which 11 were local access site injuries. All needed transfu-
sion, and seven needed surgical evacuation/repair. Three
patients had remote hemorrhage necessitating transfusion
(two gastrointestinal and one retroperitoneal). Fifteen pa-
tients (13%) had thromboembolic complications: two pa-
tients had contralateral limb arterial thromboembolism dis-
tal to the site of access necessitating emergent arterial
thrombectomy/embolectomy (both having acute occlu-
sion of existing contralateral bypasses with severe ischemia).
One arterial dissection was treated with angioplasty/stent-
ing. Twelve cases of ipsilateral distal arterial embolization
occurred. Four were treated with pulsed spray CDT and
five with emergent arterial embolectomy after CDT pulsed
spray failure, and three were treated conservatively. Addi-
tional major morbidity included compartment syndrome
necessitating fasciotomy in one patient, three nonfatal
myocardial infarctions, and acute renal failure in one pa-
tient from myoglobinuria. In summary, 2.9% of patients
treated with CDT died and 6.7% had major amputation.
The mean follow-up period after CDT was 45  36
months. The secondary graft patency rates ( standard
error) on an intention-to-treat analysis were 32% (4.9%),
25% (4.7%), and 19% (4.7%), at 1, 3, and 5 years,
respectively (Fig 1). Median secondary graft patency for
successfully lysed LEABs was 6 months. After successful
CDT, the 1-year secondary patency rate was similar in
LEABs with or without residual lesions (42% versus 45%).
The relationships between gender, graft anatomy, conduit,
days of symptoms, and immediate success CDT and sec-
ondary patency were examined in those patients with in-
frainguinal grafts (Table V). No significant associations
were detected between immediate success of CDT and
gender, graft anatomy, conduit, and days of symptoms
before CDT. Similarly, no significant differences in second-
ary LEAB patency were identified between genders, graft
anatomy, or conduit. Only 39% of patients who underwent
CDT had a patent LEAB at 6 months without any peripro-
cedural complications. Finally, no learning curve difference
was noted between early (before June 1994) and late (after
June 1994) periods for secondary patency (P  .37).
One hundred forty-nine additional hospitalizations
were necessary for recurrent lower extremity ischemia or
complications during the follow-up period. Twenty-five of
the 54 LEABs (46%) that eventually failed after initial
successful CDT had two or more reocclusive episodes, and
10 (18%) had three or more reocclusive episodes. Thirty-
three additional CDT procedures were performed to man-
age recurrent LEAB occlusion. Thirty-three operative graft
thrombectomies with or without revision were used to
manage recurrent LEAB occlusion. Twenty-three addi-
tional LEAB surgical revisions were performed to manage
graft stenoses uncovered after additional CDT or graft
surveillance. Seven of 84 LEABs (8.3%) initially salvaged
with CDT eventually became infected (six requiring major
amputation). Six of these grafts were prosthetic, all had had
multiple occlusions with need for repeat surgery, and most
had associated wound complications. Twenty of 84 LEABs
(24%) initially salvaged with CDT were eventually replaced
(four immediately and 16 after episodes of recurrent isch-
emia). Two patients died during repeat hospitalizations for
recurrent lower extremity ischemia and subsequent compli-
cations. Limb salvage rates ( standard error) were 73%
(4.6%), 63% (5.3%), and 55% (5.9%) at 1, 3, and 5
years, respectively (Fig 2). Patient survival rates ( standard
error) were 92% (2.7%), 74% (4.7%), and 56% (5.8%)
at 1, 3, and 5 years, respectively (Fig 3).
DISCUSSION
The management of LEAB occlusion represents a clin-
ical enigma for the modern vascular surgeon. Moreover,
this problem will increase in the future because of an aging
population and the exponential increase of endovascular
Table III. Anatomic location of lesions in 51 LEABs
after successful CDT
Location of lesion No. (%)
Inflow 10 (20)
Outflow 27 (53)
Intragraft 4 (8)
Inflow and outflow 10 (20)
Table IV. Complications associated with CDT
Complication No. (%)
Death 3 (2.8)
Bleeding 14 (13)
Thromboembolic 15 (14)
Myocardial infarct 4 (4)
Renal failure 1 (1)
Compartment syndrome 1 (1)
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technology for infrainguinal occlusive disease. Our experi-
ence with CDT for LEAB occlusion yields several observa-
tions regarding this patient cohort. Ninety percent of pa-
tients had limb salvage indications at the time of LEAB
occlusion at a mean age (65 years) that was approximately 5
years younger than typical limb salvage series.16-19 Perhaps
because these were younger patients, at least 40% had their
first vascular intervention for claudication. Before CDT,
60% and 34% of these patients had undergone at least two
and three prior revascularizations, respectively. Finally,
these LEABs had early failure before CDT with 20%
constructed of nonautogenous conduit in the infra-
geniculate position. In general, this is a younger vascular
population with an escalation in their vascular disease
over time.
The immediate success and durability of CDT for
LEAB occlusion in our analysis is similar in our report to
previous series and randomized trials.2,7-11 Three quarters
of the LEABs had patency restored. One quarter had
bleeding or thromboembolic complications, and roughly
half needed surgical therapy, which shows the technical
difficulties of catheter-based interventions in patients with
multiple prior revascularizations. Approximately two thirds
of LEABs salvaged with CDT had residual lesions. Most of
these lesions were managed with endovascular methods.
The long-term performance of these salvaged LEABs was
disappointing. Secondary patency dropped off markedly by
6 months (40%), with a slower attrition rate up to 5 years
(20%). No difference was seen in secondary patency rates
for any subgroup examined, which may represent a type II
error. Limb salvage rate decreased at a fairly steady rate to
approximately 50% at 5 years. The amount of morbidity
accrued during the follow-up period was concerning. A
large number of reocclusions/interventions occurred, with
one in 10 salvaged grafts eventually infected and almost one
in four of salvaged grafts eventually replaced.
Our data neither prove nor disprove that surgical ther-
apy for LEAB occlusion is preferable to CDT. There is
every reason to speculate that the short-term and long-term
morbidity in a population undergoing redo LEAB would
be substantial owing to perioperative mortality, reopera-
tions for thrombotic, bleeding, and wound complications
for open surgery comparable with complications of
CDT.16,20-23 Long-term morbidity with regards to wound
complications, lower extremity edema, graft surveillance/
revision, graft failure/replacement, and modest limb loss
over time may have been similar.13,14,16,21-23 Of note,
immediate amputation may play a role in a subset of pa-
tients as a result of age, comorbidities, minimal arterial
outflow for reconstruction, or marginal function.
Given that therapy alternatives for LEAB occlusion
appear relatively dismal, can measures be taken to reduce
this disadvantaged population of patients? It appears clear
that a subset of patients with initial intervention for claudi-
cation will eventually progress to limb threat after revascu-
larization failure. Standard clinical patterns of progression
would include: 1) patients with iliac angioplasty/stenting
followed by failure or aortofemoral bypass followed by limb
occlusions, with an eventual crossfemoral reconstruction
Table V. Relationships between gender, graft anatomy,
conduit, days of symptoms CDT and initial CDT success
and secondary patency in those patients with infrainguinal
grafts
Variable Immediate success Secondary graft patency
Gender P  .42 P  .69
Graft anatomy P  .73 P  .25
Conduit P  .85 P  .75
Days of symptoms P  .39
Fig 1. Secondary patency for 109 LEABs after CDT.
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necessary18; and 2) patients with an above-knee femoral
popliteal bypass with failures eventually resulting in a fem-
orotibial reconstruction.24,25 Although the actual percent-
age of these difficult cases created with intervention in the
claudication population is unknown, it is clear to every
vascular surgeon that once this clinical course had started,
misery is the rule rather than the exception. Therefore, one
of the clear messages of these data is to proceed with
caution when intervening for claudication.
Currently, we individualize the management of LEAB
occlusion on the basis of patient age/comorbidities, avail-
able conduit, and arterial runoff. Younger patients with
prior prosthetic infrainguinal grafts for claudication and
available saphenous conduit undergo arteriography with or
without CDT to define arterial outflow followed by saphe-
nous vein graft replacement. Older patients or those with
compromised or limited autogenous conduits available un-
dergo CDT. If successful, lesions are managed with endo-
vascular methods if possible. Although half of CDT sal-
vaged LEABs will reocclude in 6 to 12 months, half will
remain patent. Unfortunately, the number of patients in
our series was insufficient to provide reliable subset analyses
to determine which patients/grafts/lesions/conduits
might perform best. Those patients with early reocclusion
after CDT should undergo graft replacement or amputa-
tion. This strategy takes advantage of the patients who do
well with CDT and minimizes the long-term morbidity of
repetitive LEAB occlusions.
Fig 2. Limb salvage for 105 limbs after CDT for LEAB occlusion.
Fig 3. Survival in 104 patients undergoing CDT for LEAB occlusion.
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Modern LEAB occlusions represent a difficult vascular
cohort with frequent multiple revascularization failures.
Many of these patients are younger, with initial interven-
tions for claudication, and now face limb-threatening isch-
emia with significant deterioration in their antecedent vas-
cular anatomy. Although no subsequent course appears
ideal and some may conclude the poor secondary patency
rates are unacceptable, we believe an initial attempt at CDT
in many patients with liberal use of graft replacement for
failures or as an initial strategy in those with favorable
remaining conduit offers the potential to minimize the
long-term morbidity in a population with a poor natural
history.
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DISCUSSION
Dr Frank B. Pomposelli. (Boston, Mass). I have a couple of
questions.
Did you attempt to stratify your outcomes according to
whether or not the patient had a primary graft or a revised graft?
And how many patients got away cleanly, an intervention, and
then had no further complications?
Dr Mark R. Nehler. The stratification regarding whether or
not patients had had one graft or if they had two grafts or more, or
three or more, was not done. We thought about doing that, but
the numbers were small enough that I did not think it was going to
make a lot of statistical sense to do so; so, that was not done.
In terms of the patients who got away cleanly without any
complications, it would be a minority of patients, and I do not have
the exact numbers.
Dr George H. Meier III (Norfolk, Va). We are becoming
more interested in thrombolysis day by day as we do more distal
bypasses with less and less quality vein.
The real question for you is the subgroup analysis. Is there a
subgroup, particularly in the venous set, that would benefit from
thrombolysis in terms of prolonging graft patency? Our problem is
when you have got a very distal bypass with alternative vein already,
then it is very difficult for us to reconstruct that patient with
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autologous conduit a second time. And so the question for you is,
is thrombolysis in those autologous grafts beneficial?
Dr Nehler. We did do the univariate analysis looking at
conduit as a potential factor in secondary patency, looking at graft
anatomy, so above-knee popliteal versus BK, tibial versus popliteal,
and did not see any difference and presented the findings that were
not significant. But it may very well be that we do not have enough
numbers. When you take 112 grafts and then you start dividing
them up, it is not uncommon that what you find is that you just do
not have enough numbers to make those analyses. So, it may very
well be that there is a subgroup that does well, but we were not able
to identify it.
Dr John Mosley (United Kingdom). Whenever we see a
paper that deals with thrombolysis, there is always a small number
that have had renal failure. And this is presumably because of
extensive muscle necrosis. Is there a time limit you have developed
between the thrombosis occurring and when you would begin
thrombolysis?
Dr Nehler. Not per se. I would have to say that we did the
usual sorts of things to examine the patient and tried not to lyse the
grafts and limbs that had nonsalvageable muscle. But obviously
there are some gray areas and mistakes can be made. We had one
case of that in this series, so it was not an overwhelming problem,
but certainly in that case we made a mistake.
Dr Kenneth Ouriel (Cleveland, Ohio). I think we need to
remember that although the results you have shown us are quite
dismal for some subcategories of thrombolysis, there is really no
comparator group. When evaluating your results, we tend to
compare them with first time infrainguinal reconstruction. And
certainly they cannot compete with the excellent results of primary
infrainguinal bypass that we have become accustomed to. The
important issue, however, is whether your thrombolytic results do,
indeed, compete favorably with the less satisfactory results of
second and third time redo infrainguinal bypass procedures. Do
you have any information in this regard?
Dr Nehler. That is an excellent point, and that is a lot of what
we did describe in our discussion. I think the majority of these
patients would not be first time bypass candidates, based on the
demographics I showed you. It would be more of the papers of
what happens when you do a redo bypass in somebody with
multiple previous failures. And the numbers are not near as well
documented and they are not quite as successful as first time
infrainguinal reconstruction. There is going to be a lot of wound
complication. There is going to be graft surveillance issues. You are
going to have to do alternate conduits. And so by no means are we
saying that replacement grafting is going to be far superior to these
numbers. This was merely a natural history study of what happens
when we do this particular method.
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